The 2010 Patient Protection and Affordable Care Act (ACA) emphasizes preventive care. In addition to expanding insurance coverage, the ACA eliminates cost sharing for services graded "A" or "B" by the US Preventive Services Task Force (USP-STF). Although these policies have improved preventive care generally, their impact on cancer screening specifically is uncertain. Whereas a recent study showed more screening in Accountable Care Organizations, a health care model pioneered by the ACA, 1 an earlier study found increases in use of medical preventive services such as blood pressure and cholesterol checks but not in cancer screening.
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Although it may take years for screening to affect mortality, higher screening rates should quickly affect incidence. We hypothesized that the implementation of major ACA policies on January 1, 2014, would be followed by an increased incidence in early-stage breast, colorectal, and cervical cancer-3 malignant neoplasms with "A" or "B" screening grades from the USPSTF.
Methods | We compared age-adjusted incidence rates of earlystage breast, colorectal, and cervical cancer in the first 9 months of 2013 (pre-ACA) and the last 9 months of 2014 (post-ACA) with an intervening 6-month "wash-in" period. Incidence rates were per 100 000 person-years and age-adjusted to the 2000 US Standard Population. To assess for change between pre-and post-ACA, we computed the incidence rate ratios (IRRs) and associated 95% confidence intervals. Then, using weighted least squares (weighting by the inverse of the variance) with a log link, we ascertained whether the relative difference in IRRs (ie, ratio of IRRs) for early-stage disease varied in a statistically significant fashion compared with locally advanced/ metastatic disease. The relative difference in IRRs was estimated by exponentiating the difference-in-differences (DID) of the log IRRs. To generate the incidence rates and IRRs, we used SEER*Stat Version 8.3.4. All other analyses were performed using SAS, version 9.4. The study received an institutional review board waiver from the Brigham and Women's Hospital.
Results | From pre-to post-ACA, the incidence of early-stage breast cancer increased from 55.5 (95% CI, 54.6-56.3) to 56.9 (95% CI, 56.0-57.7) cases per 100 000 person-years, with an IRR of 1.025 (95% CI, 1.003-1.048). Furthermore, the difference in IRRs was significantly greater in early vs locally advanced/metastatic stages (DID, 1.050; 95% CI, 1.006-1.098; P = .03) ( Table) .
The incidence of early-stage colorectal cancer increased from 13.5 (95% CI, 13.0-14.1) to 15.3 (95% CI, 14.7-15.9) cases per 100 000 person-years, with a pre-to post-ACA IRR of 1.132 (95% CI, 1.07-1.198). Similarly, the change in incidence rates was significantly greater in early vs locally advanced/ metastatic stages (DID, 1.112; 95% CI, 1.030-1.200; P = .006). This pattern was not seen in cervical cancer. Discussion | We found that incidence of early-stage breast and colorectal cancer increased after the adoption of the ACA, whereas it did not vary for late-stage cancer. Although screening itself was not assessed, the trend is consistent with modest but immediate increases in colorectal and breast cancer screening following the ACA. Our finding that there was no change in detection of early-stage cervical cancer is consistent with a previous report showing that the dependent coverage expansion to age 26 years did not affect the use of the Papanicolaou test in that population.
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Limitations of this observational study include assessment of only 1 year pre-and post-ACA, potential for unmeasured confounders, and unrelated background epidemiological trends, as well the inherent limitations of the difference-in-differences study design.
Despite these limitations, these results are consistent with a small but positive impact of the ACA on use of recommended cancer screening, which may vary by cancer site. Recent proposals for repealing the ACA would increase the uninsured population by tens of millions.
6 This could easily erase these modest gains.
Maxine Sun, PhD, MPH Alexander P. Cole, MD Stuart L. Lipsitz, ScD Quoc-Dien Trinh, MD
Validity of Surrogate End Points for Prostate Cancer
To the Editor A valid surrogate end point is a substitute for a true end point that allows conclusions about the effect of treatment on the true end point to be drawn sooner than with a true end point. Royce et al 1 argued that a prostatespecific antigen nadir value greater than 0.5 ng/mL is a good surrogate end point for all-cause mortality in men with prostate cancer. They base their claim on the proportion of treatment effect explained (PTE) of 103.86%. However, PTE is not a reliable measure of surrogacy. First, the confidence intervals, which were not reported, are typically too large to be useful, 2 particularly if the effect of treatment on the true end point (not adjusted for the surrogate end point) is small. 
